SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Almac sees growing demand for non-GMP contracting

By Gareth Macdonald , 15-Nov-2011

Almac sees growing demand for non-GMP contracting
Almac sees growing demand for non-GMP contracting
Loading...

Almac says growing demand for non-GMP manufacturing work rather than competition was the key driver for expansion of its product development services business.

Outsourcing-pharma.com spoke with Almac’s David Downey at CPhI 2011 in Frankfurt, Germany, who said that the investment Almac made in its plant in Craigavon, Northern Ireland late last month would allow the firm to take manufacturing projects from early development through to GMP.

We what will do is double our footprint from a product development perspective…what this will allow us to do is work in a non-GMP environment, be very reactive and…then scale it up into a GMP environment.

He added that: “Currently we have challenges with the capacity we can allocate from the existing facility and that has very much driven the investment.”

Downey rejected the idea that European contractors need to make such investments in the face of competition from Asia, and instead argued that experience gives Western contract manufacturing organisations (CMOs) the edge.

We face challenges from Asia and China now in terms of product development services, but I think for companies that are trying to do complex transfers, complex product development work really you want to be working with someone that understands and has good experience of what you are trying to achieve.

The investment in Craigavon is one of a number Almac has made over the last few weeks, the most recent of which was the addition of extra high potency active pharmaceutical ingredient (HPAPI) production capacity .

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE
Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO Agneta Bergvall says drugmakers' efforts to make pharmaceutical manufacturing green are worth...

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Will Downie

Senior VP Global Vusiness Development & Marketing, Catalent

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

Quincy Mattingly

Regional Manager, AlpVision

Cobra Biologics talks recent fill finish acquisition and future growth plans

Cobra Biologics talks recent fill finish acquisition and future growth plans

Philip Ridley-smith

Business Development & Marketing Manager, Cobra Biologics

Catalent says sharing with industry will not dull competetive edge

Catalent says sharing with industry will not dull competetive edge

Kurt Nielsen and Cornell Stamoran

Various, Catalent

Bend Research hunting new partnerships to boost bioavailability offering

Bend Research hunting new partnerships to boost bioavailability offering

David Lyon and Karen Coppens

Various, Bend Research and Dow

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Andrea Schiefer

VP of European clinical operations and executive director of pharmacovigilance,...

Home visits = regulatory thumbs up? ResearchNurses.co thinks so

Home visits = regulatory thumbs up? ResearchNurses.co thinks so

Sue Mackay

Research nursing team manager, ResearchNurses.co

Consolidation prevalent in industry, says third largest CMO

Consolidation prevalent in industry, says third largest CMO

Brad Carlson

VP Marketing 7 Sales, Aenova

Catalent commits to ADCs by upping its stake in Redwood

Catalent commits to ADCs by upping its stake in Redwood

Aileen Ruff

Global Strategic Marketing Director, Biologics and Sterile Technologies at Catalent...

Kemwell Talks Expansion and Approvals in India and the US

Kemwell Talks Expansion and Approvals in India and the US

Christian Ahlmark

Director of Corporate Development , Kemwell Biopharma

AMRI Exec Discusses 'New Bar' in FDA Enforcement

Following the completion of remediation efforts to deal with an FDA warning letter, Chris...

Happy holidays from William Reed Business Media!

Happy holidays from William Reed Business Media!

The working year is almost done, time to pause from ‘the business’ and embrace...

Aesica says academic partnerships are key for CMOs

Aesica says academic partnerships are key for CMOs

Alan Raymond

Sales & Marketing Director, Aesica Pharmaceuticals

Wockhardt targets CMO space for diversification

Wockhardt targets CMO space for diversification

Tom Salus

Associate Vice President, Business Development - Contract Services, Wockhardt

Kemwell and Boehringer set to finish biologics plant in India

Kemwell and Boehringer set to finish biologics plant in India

Christian Ahlmark

Director of corporate development , Kemwell